Cancer immunotherapy works by stimulating and strengthening the body's anti-tumor
immune response to eliminate cancer cells. Over the past few decades, immunotherapy has …

Breast cancer heterogeneity determines cancer progression, treatment effects, and
prognosis. However, the precise mechanism for this heterogeneity remains unknown owing …

Current success of immunotherapy in cancer has drawn attention to the subsets of TH cells
in the tumor which are critical for activation of anti-tumor response either directly by …

ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have recently entered into the
therapeutic scenario of metastatic breast cancer. However, only a proportion of patients …

Introduction Immune checkpoint inhibitor (ICI) monotherapy appears to be effective in a
small cohort of patients with metastatic triple negative breast cancer (mTNBC). This supports …

Background Breast cancer (BRCA) is a malignant tumor with high morbidity and mortality,
which is a threat to women's health worldwide. Ferroptosis is closely related to the …

Breast cancer is the most commonly diagnosed and the most lethal cancer in females both
in China and worldwide. Currently, the origin of cancer stem cells, the heterogeneity of …

Breast Cancer (BC) is the second most frequent cause of cancer death among women
worldwide and, although there have been significant advances in BC therapies, a significant …

Simple Summary The assessment of tumor-infiltrating lymphocytes (TILs) is gaining
acceptance as a robust biomarker to help predict prognosis and treatment response. We …

Highlights•CDK12/13 inhibition promotes immunogenic cell death (ICD) in breast
cancer.•SR-4835 and anti-PD-1 treatment enhances DC activation.•SR-4835 enhances the …